Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of GB001 in Patients With Chronic Rhinosinusitis With or Without Nasal Polyps
NCT03956862 is registered in ClinicalTrials.gov with GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of GB001 in Patients With Chronic Rhinosinusitis With or Without Nasal Polyps
- Lead sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 16, 2019
- Completion date
- August 5, 2020
- Enrollment
- 97 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.
chronic rhinosinusitis with nasal polyps (crswnp), chronic rhinosinusitis without nasal polyps (crssnp)